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Consensus Meeting Group on
Antimicrobial Stewardship
Programme
Objective. To discuss the implementation of an ‘antimicrobial stewardship pro-
gramme’ as a means to improve the quality of antimicrobial use in a hospital
setting in Hong Kong.
Participants. Consensus working group on ‘antimicrobial stewardship pro-
gramme’, The Scientific Committee on Infection Control, Centre for Health
Protection, Department of Health, comprised 11 experts. The remit of the work-
ing group was to discuss the rationale and requirement for optimising antimicro-
bial prescriptions in hospitals by the introduction of an ‘antimicrobial stewardship
programme’.
Evidence. PubMed articles, national and international guidelines, and abstracts
of international meetings published between January 2000 and December 2004
on programmes for improving the use of antimicrobials in hospitals. Only
English medical literature was reviewed.
Consensus process. Data search was performed independently by three mem-
bers of the working group. They met on three occasions before the meeting to
discuss all collected articles. A final draft was circulated to the working group
before a meeting on 3 January 2005. Five commonly asked questions about an
‘antimicrobial stewardship programme’ were selected for discussion by the
participants. Published information on the rationale, components, outcome
measures, advantages, and disadvantages of the programme was reviewed.
Recent unpublished data from local studies of an ‘antimicrobial stewardship
programme’ were also discussed. The timing, potential problems, and practical
issues involved in the implementation of an ‘antimicrobial stewardship
programme’ in Hong Kong were then considered. The consensus statement was
circulated to and approved by all participants.
Conclusion. The continuous indiscriminate and excessive use of antimicrobial
agents promotes the emergence of antibiotic-resistant organisms. Antimicrobial
resistance substantially raises already-rising health care costs and increases
patient morbidity and mortality. Pattern of prescriptions in hospitals can be
improved through the implementation of an ‘antimicrobial stewardship
programme’. A ‘universal’ and ‘continuous’ ‘antimicrobial stewardship
programme’ should now be established in Hong Kong hospitals.
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Introduction
The discovery of penicillin by Alexander Fleming was a
major breakthrough in the battle against infectious diseases.
Today, antibiotics are the most widely prescribed drugs, yet
their value is being threatened by an alarming increase in
antibiotic-resistant bacteria. Multidrug-resistant strains of
many commonly encountered bacteria such as Staphyloco-
ccus aureus, Escherichia coli, Klebsiella spp, Neisseria
gonorrhoeae, and Pseudomonas aeruginosa have already
emerged. In Hong Kong, there is evidence that the drug-
resistant pneumococci, methicillin-resistant Staphylococcus
aureus (MRSA), extended-spectrum β-lactamases (ESBLs)–
producing Enterobacteriaceae, and carbapenemase-
producing Acinetobacter are more prevalent than in many
other countries.1 The indiscriminate and excessive use of
antimicrobial agents within hospitals promotes the emer-
gence of such antibiotic-resistant organisms. Strategies
that optimise antimicrobial use are thus essential if this
microbial threat is to be minimised.
The World Health Organization (WHO) defines optimal
prescribing (prudent prescribing) as “the cost-effective
use of antimicrobials which maximizes their clinical thera-
peutic effect, while minimizing both drug-related toxicity
and the development of antimicrobial resistance.”2,3 In the
United Kingdom, the Clinical Prescribing Subgroup
(established in September 1999 as part of the response to
the House of Lords report on ‘Resistance to Antibiotics and
Other Antimicrobial Agents’4) uses a more comprehensive
definition: “The use of antimicrobials in the most appropri-
ate way for the treatment or prevention of human infectious
diseases, having regard to the diagnosis, evidence of clini-
cal effectiveness, likely benefits, safety, cost, and propen-
sity for the emergence of resistance. The most appropriate
way implies that the choice, route, dose, frequency and dura-
tion of administration have been rigorously determined.” In
line with the above concepts, optimal antibiotic use should
mean both ‘less’ use (ie less unnecessary use), and ‘appro-
priate’ use (ie not only the right antibiotic but also the right
dosage, route, and duration to effect a cure while minimis-
ing side-effects and the development of resistance accord-
ing to current knowledge). In hospitals, the concept of an
‘antimicrobial stewardship programme’ (ASP) as a means
to achieve optimal prescribing is being increasingly dis-
cussed and adopted. This consensus group was formed to
discuss the implementation of an ASP in Hong Kong.
Consensus process
Data in this review were identified by searches of PubMed,
references from relevant articles, national and international
guidelines, and abstracts of recent international meetings
on programmes to improve the use of antimicrobials and
reduce bacterial resistance in hospitals. Search terms were
“antibiotics”, “antimicrobials”, “antimicrobial agents”,
“steward”, “stewardship”, “antimicrobial resistance”, and
“program”. Recent reviews on related topics were also
checked for additional references. Only papers in English
language were reviewed. The review focused primarily on
data published during the 5-year period from January 2000
to December 2004. The search was performed independ-
ently by three clinicians who met on three occasions to
discuss all collected manuscripts and presented a final
draft to all members of the consensus group. The group
comprised local and overseas experts in the fields of
clinical microbiology, clinical virology, dentistry,
epidemiology, infection control, infectious diseases,
and safety and environmental protection. The consensus
meeting on “Optimizing antimicrobial prescriptions in
hospitals by antimicrobial stewardship program in Hong
Kong: rationale and requirement”, organised by the
Scientific Committee on Infection Control, Centre for
Health Protection, Department of Health, Hong Kong,
was held on 3 January 2005. The document was discussed
and subsequently revised before being re-circulated and
finalised.
Questions and discussion
What is the rationale for optimising antimicrobial
use?
The impetus behind the promotion of optimal antimicrobial
use lies in the growing concern about antimicrobial
resistance. As antimicrobial resistance increases, many
previously time-honoured, first-line therapies (eg ampicil-
lin for E coli, erythromycin for Streptococcus pneumoniae,
fluoroquinolone for N gonorrhoeae) are rapidly losing
their efficacy and are becoming obsolete.3 Antimicrobial
resistance substantially raises already-rising health care
costs: more expensive second- and third-line drugs must
be prescribed; the infectious period for individuals is
prolonged; morbidity, length of hospital stay, and mortality
are increased. Infection with MRSA is a prime example.
Nosocomial bloodstream infection prolongs hospitalisa-
tion by a mean of 8 days, longer than similar infections
caused by methicillin-susceptible S aureus. This results in a
trebling of direct cost.5 Treatment of MRSA may increase
the cost per case by as much as US$2500 to $3700.6 In the
United States, infection caused by nosocomial antibiotic-
resistant organisms is estimated to result in an additional
expenditure of US$1.3 to $4 billion yearly.7
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There is an increasing amount of data linking antibiotic
use with the development of bacterial resistance.3 In-vitro
studies reveal that drug exposure selects for resistance,
ecological studies correlate drug exposure with resistance,
and clinical studies reveal that patients prescribed
antimicrobial drugs are more likely to be colonised or
infected with resistant bacteria. In the last two decades,
bacterial resistance has evolved and spread rapidly in the
health care setting. The treatment of several multidrug-
resistant pathogens that have become widespread, includ-
ing MRSA, vancomycin-resistant enterococci (VRE),
ESBLs-producing Enterobacteriaceae, and multidrug-
resistant Pseudomonas aeruginosa (MRPA) is difficult.
This is largely due to the overuse and misuse of antimicro-
bial drugs.8
As many as 30% to 40% of hospital in-patients in
developed countries are prescribed antimicrobial agents.
Reasons for prescription vary widely and prescriptions
are often suboptimal, indicating a need to standardise
antimicrobial use.9,10 An attempt was made as early as the
1970s to assess the quality of antimicrobial drug prescrip-
tion using specifically designed flowchart and quality
indicators.11 When such quality indicators were applied
as tools for clinical audit of antimicrobial prescription,
49% to 55% of prescriptions for hospitalised patients
were reported to be suboptimal.12 This adversely affects
patient outcome and increases the risk of antimicrobial
resistance.13-16 For example, the selection of antimicrobial
resistance in nosocomial pneumonia has been linked to
suboptimal antimicrobial exposure.15 In Hong Kong,
suboptimal antibiotic prescription has been reported to
contribute strongly to the emergence of levofloxacin-
resistant S pneumoniae.16
The problem of antimicrobial resistance may be further
complicated by an uncertain supply of new agents17-19 and a
dwindling number of companies investing in antimicrobial
agents.20 In the 1930s and 1940s, four new classes of
antibiotics were approved: sulphonamides, β-lactamase,
aminoglycosides, and chloramphenicol. In the 1950s
and 1960s, a further six antibiotic classes were added:
tetracycline, macrolides, glycopeptides, rifamycins,
quinolones, and trimethoprim. From the 1970s to 1990s,
no novel classes were licensed and all new drugs were
derivatives of existing agents. Between 2000 and 2004,
only two new classes of antibiotics have been approved:
oxazolidinones (linezolid) and the cyclic lipopeptides
(daptomycin). Additional novel antibacterial agents may
be a future possibility but improvements by clinicians in
their use of existing antibiotics is imperative.
What is an ‘antimicrobial stewardship programme’?
Who are the advocates?
The dangerous repercussions of antibiotic abuse have
been recognised by institutions and hospitals for over half
a century.21-25 Professional societies and public health
guardians including the WHO, Infectious Diseases Society
of America (IDSA), Alliance for the Prudent Use of
Antibiotics, Food and Drug Administration, Centers
for Disease Control and Prevention, and National Institutes
of Health all support programmes that promote optimal
antimicrobial use,26,27 and some have proposed an action
plan.2,28
‘Antimicrobial stewardship’ involves the optimal
selection, dosage, and duration of antimicrobial treatment
that results in the best clinical outcome for the treatment
or prevention of infection, with minimal toxicity to the
patient and minimal impact on subsequent resistance.29
In practice, this involves prescribing antimicrobial therapy
only when it is beneficial to the patient, targeting therapy
to the desired pathogens, and using the appropriate drug,
dosage, and duration. It should not be viewed simply as
reduced use or a strategy for cost containment. Instead,
minimising exposure to drugs, performing dosage
adjustments, reducing redundant therapy, and targeting
therapy to the likely pathogens, can be viewed as a strategy
to enhance patient safety.
The programme involves a multidisciplinary,
programmatic, prospective, interventional approach
to optimising the use of antimicrobial agents. The
multidisciplinary team typically includes the clinical
microbiologist, infectious diseases specialist, infection-
control practitioner, and clinical pharmacist. Recruitment
of members from other medical specialties, such as surgery
and paediatrics, is also recommended. Multiple approaches
have been employed to enforce hospital policies that limit
or control antimicrobial use (Box). Under the auspices of
an ASP, several behavioural methods have been used
successfully to effect changes, including problem-based
education, consensus guidelines, peer review, concurrent
review, data feedback, computer-based reminders, financial
incentives, and the use of opinion leaders.30,31
The importance of a committed hospital administration
is well recognised. The Society for Healthcare Epidemio-
logy of America (SHEA) consensus statement, titled
“Strategies to prevent and control the emergence and
Methods to implement antimicrobial control
1. Provision of written hospital guidelines
2. Educational efforts aimed at changing prescribing practices
of physicians
3. Providing consultation from clinical microbiologist/infectious
diseases specialist
4. Restriction of hospital formulary through the Drug and
Therapeutics Committee
5. Utilisation review with guidelines for rational and appropriate
usage
6. Ongoing monitoring and analysis of antimicrobial usage
7. Ongoing surveillance of antimicrobial susceptibility
8. Monitoring adherence to advice on choice of antimicrobial
agents
9. Feedback to physicians
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spread of antimicrobial-resistant microorganisms in
hospitals,”32 is the first document to state that without
clear commitment from the hospital leadership, programmes
to improve and optimise antibiotic use will never be
successful. The willingness and interest of infectious
disease specialists or infection-control practitioners will
never be sufficient if the hospital administration does not
emphasise antibiotic control as a priority. These sentiments
are echoed in the SHEA/IDSA guidelines33 and by several
opinion leaders.34,35
The development of programmes to control and promote
the rational use of antimicrobial drugs has become more
prevalent in the United States, United Kingdom, and
European countries, in the past few decades in an attempt
to curb the development of multidrug-resistant bacteria
Table 1.  Methods and outcomes measured in recently published antimicrobial stewardship programmes37-42
Hospital size, Place Length Patient outcomes Bacterial resistance Impact on antibiotic
primary strategy of study and infection outcomes use and costs
period
575-Bed, prior US 6 months No difference in survival in Significant reduction in Significant reduction in the
authorisation40 patients with gram-negative resistance rates use of the following
bacteraemia; no difference restricted agents:
in the time from positive aztreonam, ceftazidime,
blood culture to receipt of imipenem, ticarcillin-
appropriate antibiotics; no clavulanate; first-year
difference in infection reduction in total
(bacteraemia)-related length antimicrobial expenditure
of stay was US$803 910
2500-Bed, prior Italy 1 year Not determined Not determined Usage and expenditure in
authorisation42 the restricted group of
antibiotics decreased by
78.5% and 53.5%,
respectively; usage in the
unrestricted antibiotics
increased by 32.6%
250-Bed, concurrent Argentina 2 years No difference in crude Decreasing resistance to Total cost saving was
review37 mortality; the mean ceftriaxone by Proteus US$913 236
hospitalisation for infected mirabilis and Enterobacter
patients decreased cloacae; decreasing rate of
methicillin-resistant
Staphylococcus aureus;
decreasing resistance to
carbapenem by
Pseudomonas aeruginosa
Medium size, concurrent US 7 years Not determined Significant decrease in 22% Decrease in the use
reviews41 nosocomial infections of intravenous broad-
caused by Clostridium spectrum antibiotics
difficile; significant decrease (P<0.0001); use of third-
in nosocomial infections generation
caused by resistant cephalosporins and
Enterobacteriaceae aztreonam decreased
(P=0.02) rapidly during the study
period (from 24.7 DDD*/
1000 patient-days to
6.2 DDD/1000 patient-
days; P<0.0001); cost
savings of US$200 000 to
$250 000 per year
731-Bed, concurrent US 3 years No difference in the mortality No significant change in 28% Reduction of broad-
review38 and length of stay resistance rates of spectrum antimicrobial
common nosocomial use
gram-negative organisms
80-Bed, concurrent review US 4 years No difference in overall and No significant change in Antibiotic expenditure
and prior authorisation39 infectious disease–specific susceptibility patterns of decreased by 53%;
mortalities; no difference in bacteria intravenous drugs
relapse rate; no difference in accounted for >90% of
hospitalisation for all patients cost savings; significant
and antibiotic-treated decrease in usage of
patients; no difference in re- broad-spectrum
hospitalisation rate antibiotics; using DDD
data: reduction in overall
antimicrobial use: 36%;
reduction in intravenous
antimicrobial use: 46%
* DDD denotes defined daily dose
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in hospitals.36 Likewise in Hong Kong, there is consider-
able public, political, and professional awareness of the
increasing burden of antimicrobial resistance.
Is an ‘antimicrobial stewardship programme’
beneficial? How can benefits be documented? Does
an ‘antimicrobial stewardship programme’ result in
better and more optimal antibiotic use in the hospital
setting?
An ASP has several benefits (Table 137-42). It reduces the
use of targeted antibiotics and antimicrobial expenditure.
Nonetheless crude or infection-related mortality rates,
time to receipt of appropriate antibiotics, and length of
hospitalisation are not affected by the implementation of
ASPs.37-40 These findings are important because they
indicate that patient safety is not compromised. The
impact on antimicrobial resistance varies because the
factors that promote resistance are complex.43,44 A strong
relationship exists between certain antibiotic classes
and multidrug-resistant pathogens: vancomycin and
VRE; third-generation cephalosporins and ESBLs; as well
as fluoroquinolones and MRSA and MRPA. At an institu-
tional level, programmes designed to limit utilisation of
agents that exert greater effect on the above have reduced
specific resistance rates.
Measurement and monitoring is an essential part of the
programme. After an initial implementation of a restricted
formulary and antimicrobial approval system, the team
should meet regularly to review and update the formulary,
assess its effectiveness, provide and coordinate ongoing
physician education, and analyse antimicrobial utilisation
data within the hospital. The programme should be dynamic
and continually reassessed, with new components added
and unsuccessful components deleted.
To allow for accurate intra- and inter-institutional
comparisons, confounding differences in expenditure
related to acquisition costs and variations in the amount
of individual antibiotic used for individual patients should
be standardised. Each antimicrobial agent should be
assigned a fixed or defined daily dose (DDD) in the manner
recently supported by the WHO.45 Defined daily dose is an
assumed average maintenance dose per day of a drug used
for its main indication in adults. It does not necessarily
reflect the recommended or prescribed daily dose. Thus, it
can give a rough estimation of consumption of the drugs
being monitored but is independent of price or formulation.
The following measures can be calculated as standardised
rates (in terms of DDDs per denominators): (1) per patient
admitted, (2) per patient treated, (3) per 1000 hospital-days,
and (4) per 1000 treatment-days.
Is this the right time for Hong Kong to introduce an
‘antimicrobial stewardship programme’? Are we too
early or are we too late, and why?
In Hong Kong, few would dispute the threat from antimi-
crobial resistance and the needless expenditure associated
with excessive antimicrobial use.46 Recent surveys show
that suboptimal antimicrobial prescriptions may be com-
monplace in our hospitals,47 and such practice can be
improved. In the two university hospitals, a recent prospect-
ive study found that 76% of antibiotic prescriptions for
patients hospitalised with exacerbated chronic obstructive
pulmonary disease were unjustified according to the
prevailing Global Initiative for Chronic Obstructive Lung
Disease guidelines.47 A year later in 2004, real-time audit
of “big gun” antibiotics in two hospitals revealed that 20%
to 25% of the prescriptions were not justified or suboptimal.
The most common errors included treatment of colonisation,
omitting to use a more specific and equally effective
alternative antimicrobial or less toxic antimicrobial, and
inappropriate duration (personal communication). In
another prospective study of antibiotic combinations
prescribed over a 6-month period, one of the agents was
redundant in 80% of 200 prescriptions.47
In response to an increasing demand for a local
antibiotic reference, a multidisciplinary group produced
the IMPACT (Interhospital Multi-disciplinary Programme
on Antimicrobial ChemoTherapy) document in 1999 with
the vision of introducing antimicrobial stewardship into
the Hospital Authority (HA) hospitals.46 Despite some
encouraging progress in the past 5 years, there are
problems related to implementation, process evaluation,
and programme sustainability. In order to properly address
the complex issues in antibiotic prescription, specific
mechanisms and designated manpower are required to
identify the institutional pattern of use, areas of misuse,
and all the suboptimal indications, dosages, formulations,
routes, and duration. The issue of sustainability should
be dealt with at managerial and professional levels. With-
out institutional priority, and clearly defined responsibili-
ties and accountability, real improvement is unlikely.48
Ongoing activities conducted by properly trained personnel
such as infection-control doctors and nurses are essential
for the implementation of infection-control policies.
Infection-control staff and staff promoting an ASP have
overlapping roles. Thus it may be prudent to expand the
role of existing infection-control teams and introduce ‘anti-
microbial and infection-control officers’ and ‘antimicrobial
and infection-control nurses’.
More action is required in areas where antimicrobial
resistance is most serious. In Hong Kong, there is evidence
that antibiotic resistance of some important nosocomial
pathogens is worse than that in many other parts of the
world.1 Methicillin-resistant Staphylococcus aureus is
endemic among local hospitals with 30% to 50% of all S
aureus resistant to methicillin. In intensive care units,
70% to 80% of S aureus is MRSA. Most MRSA are also
resistant to a number of other drugs. The incidence of
VRE in Hong Kong is low at present: the first isolate was
imported in 1997. Since then sporadic cases have been
identified in at least five public and one private hospitals.
In two public hospitals, clustering and nosocomial trans-
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mission has been reported. The ESBLs are bacterial
enzymes that are capable of inactivating third-generation
cephalosporins. A survey of four Hong Kong hospitals
in 1997/1998 revealed rates of 6% to 23% for Klebsiella
pneumoniae and 9% to 14% for E coli.1
In the United States, a “Public health action plan to
combat antimicrobial resistance (action plan)” was
developed in 1999. In the United Kingdom, significant
progress has been made in optimising the clinical use of
antimicrobials since 2000 in terms of governmental
directives, strategy, and action plan.28,49 Similar initiatives
have also been launched in Taiwan and South Korea. Many
studies have found that optimisation of antibiotics in hospi-
tals is feasible, safe, and effective. A diversity of approaches
have been reported and the experience accumulated so far
indicates that a multi-faceted ‘stewardship’ approach has
clear advantages.29,34-37,39,41,50,51 A systematic review of the
quality of interventions to improve hospital antibiotic
prescription reveals that the existing approaches are not
ideal and further refinement will be required.52
A ‘universal’ and ‘continuous’ ASP should now be
established in Hong Kong hospitals. With the establishment
of the Centre for Health Protection, this is a timely initiative.
A closer collaboration between partners in different sectors
including the HA, Department of Health, Hong Kong
Medical Association, the private hospitals, the two medical
schools, patient’s groups, and pharmaceutical companies
is essential. During the process of introduction, the Centre
for Health Protection could take the lead and work out the
directions and strategies for public and private hospitals.
Implementation of an ASP should not be hasty. Instead,
definite targets should be set in order to monitor the uptake,
progress, effectiveness, and safety of such a programme.
The assistance of local experts who have the experience of
ASP should also be sought.
What are the disadvantages of an ‘antimicrobial
stewardship programme’? What problems have been
reported? Are there any arguments against having
the programme? Is there a role for an alternative
mechanism?
The stewardship programme involves proactive monitoring
and feedback. An alternative approach is ‘no control’
(ie only by passive means). Such an approach relies heavily
on the distribution of national guidelines and has been
shown not to work.53 Guidelines are seldom studied
thoroughly by clinicians, and even if read, are unlikely
to be incorporated into everyday practice. There are con-
cerns about ASP that should also be addressed (Table 232).
The perception of ‘threatened physician autonomy’ can
be a significant hindrance. Previous studies and local
experience have indicated that this is often an ‘emotional’
response that can be resolved by immediate concurrent
feedback, consensus building, involvement of institutional
opinion leaders, and attention to process measures.54-56
Similar programmes have been launched successfully in
some HA hospitals for other drugs, including the statins,
calcium channel blockers, and acid-suppressive agents.
Another barrier to implementation is the perception that
an ASP is solely cost-driven and patient safety may be
compromised. For this reason, recent reports have empha-
sised the inclusion of quality indicators such as time to
reception of appropriate empirical antibiotics. Other
suggested indicators include: (1) clinical outcomes of
bacteraemia due to gram-negative organisms,40 (2) mortal-
ity for all patients, for those treated with antimicrobials,
and for those with an infection, (3) duration of hospital stay
for all patients and for those treated with antimicrobial
drugs, and (4) re-hospitalisation rate within 30 days after
discharge for all patients and those treated with antimicro-
bial drugs.39 As in any quality improvement programme,
a financial incentive is important to secure support by
Table 2.  Potential barriers to reaching the strategic goals32
Barrier Countermeasures and improvement strategies
Ownership and accountability
Lack of ownership and accountability for recognising and reporting Designate responsibility and accountability for the process
trends
Failure to integrate work of laboratory, infection-control, medical, Set up a multidisciplinary team to develop a collaborative system
nursing, and care-unit staff and monitor results
Staff knowledge and practice
Lack of time for the laboratory and/or infection-control staff to Ensure adequacy of laboratory and infection-control staffing and
generate and analyse data prioritise activities of staff so that data can be generated and
analysed
Lack of time for health care providers to examine and discuss data, Report data in an easy-to-read/interpret format and, when
and inconsistent or erroneous interpretation of data by staff appropriate, include data interpretation in the report
Physician attitudes
Lack of trust in the hospital administration Use a data-driven approach to cultivate trust, eg communicate
regularly with physicians about trends in antimicrobial usage, cost,
and resistance, feedback to individual physicians about their
performance results
Expertise
Lack of expertise in biostatistics (eg presenting trends and Ensure availability of consultants, especially when designing
analysing data) analytical strategy and interpreting trend data
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the hospital management. The ASP is no exception. Good
leadership and effective communication are essential to
keep members, prescribers, and patients focused on the
problem. This may be enhanced by the establishment of
a multidisciplinary steering committee, and by regular use
of data feedback on the patterns of use, patient outcomes,
and antimicrobial resistance data. In principle, committee
members should have a strong sense of commitment and
cooperation. The composition of the multidisciplinary
steering committee may be unique to each institute.
Strategic directions
In the face of rising rates of drug resistance among micro-
organisms and no promise of novel antibiotics, strategies
are needed to minimise the development and spread of
antimicrobial resistance. These strategies have in common
three key and inter-related components: surveillance,
prudent antimicrobial use, and infection control. With
regard to promoting prudent antimicrobial use through
implementation of ASP in the hospital setting, the present
meeting group proposed the following strategic directions.
Focus on antimicrobial resistance containment
Containment of antimicrobial resistance is the main
rationale for promoting optimal antimicrobial use. Since
antimicrobial resistance may spread across health care
boundaries, efforts directed at their containment by promot-
ing better use of existing antimicrobial drugs should be on
a territory-wide basis, and involve the public and private
sectors. The hospital-based component should be part of a
more comprehensive strategy for Hong Kong to be centrally
coordinated by the Centre for Health Protection.
Focus on overcoming existing barriers to prudent
prescribing by coordinated efforts
The concept of promoting prudent antimicrobial use by
antimicrobial stewardship has clear merits. It is supported
by a number of international and professional bodies, and
should be given higher priority by hospitals in Hong Kong.
In promoting the implementation of ASP, there should be
coordinated efforts by professionals, administrative staff,
regulatory agencies, pharmaceuticals, and the public
directed at overcoming the existing barriers through a range
of measures such as education, guidelines, prescribing
support, organisational support, feedbacks, and data-driven
communications. As an initial step, each institute or hospi-
tal will need to form a steering group to identify the institu-
tional issues and priorities, and to devise a working plan.
Focus on health care quality improvement
The implementation of ASP to promote prudent antimicrobial
use may be viewed as an example of quality improvement.
Quality indicators and timely feedback of data are essential to
safeguard health care quality. Before launching, specific pro-
gramme targets should be set and process and outcome meas-
ures laid down. Subsequently, programme findings should be
regularly monitored and feedback provided to parties concerned.
Conclusion
Antimicrobial drug resistance is an important public health
threat because it endangers our ability to effectively treat
infection. A multi-faceted approach that involves the
continuous application of a package of interventions should
be implemented at regional and international levels. In the
health care setting, efforts should focus on infection
prevention, effective diagnosis, early treatment, wise use
of antimicrobials, and breaking the chain of transmission.57
In Hong Kong, there is room for improvement in the use of
antimicrobial drugs in hospitals. Recent research indicates
that improvement in the pattern of prescriptions is feasible
and can be implemented by means of ASP in a safe,
scientific, and professional manner. As antibiotic-resistant
bacteria become more widespread, such initiatives will
become increasingly important. As the fight against
antimicrobial resistance continues, a major challenge in
future will be maintaining the viability of and sustaining an
ASP in the long term.
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